[TNF-alpha gene therapy for nonimmunogenic tumor using immunogenic variant induced with mutagen (N-methyl-N'-nitro-N-nitrosoguanidine)].
We have already reported that a combination of TNF-alpha and immunogenic variant was effective for immunotherapy of nonimmunogenic tumor. Immunogenic variants (A2 and A7) were obtained from nonimmunogenic fibrosarcoma (parent cell: 1767-3) by mutagen treatment with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). In this study, we studied about the possibility of TNF-alpha gene immunotherapy for nonimmunogenic tumor. We established two types of TNF-alpha producing cell lines. One is TNF-alpha producing nonimmunogenic variant (1767 TR 2), and another is TNF-alpha producing immunogenic variant (A7 TR3). We compared them about the ability of producing specific immunity against parent tumor. TNF-alpha producing immunogenic variant (A7TR3) could induce strong specific immunity to parental cell compared to TNF-alpha producing nonimmunogenic variant (1767TR2). Immunogenicity of tumor is very important when we want to perform TNF-alpha gene immunotherapy against cancer.
Mekata
E
E
1st Department of Surgery, Shiga University of Medical Science, japan.
Terata
N
N
Kodama
M
M
D000818:Animals; D000940:Antigenic Variation; D005354:Fibrosarcoma / Q000276:immunology / Q000628:therapy*; D015316:Genetic Therapy; D007167:Immunotherapy; D008769:Methylnitronitrosoguanidine; D051379:Mice; D008809:Mice, Inbred C3H; D009153:Mutagens; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics* / Q000276:immunology
D009153:Mutagens; D014409:Tumor Necrosis Factor-alpha; D008769:Methylnitronitrosoguanidine